Leveraging Next-Generation Sequencing (NGS) for Adventitious Agent Testing
📅 OCTOBER 6, 2026
🕘 11:00 EST | 08:00 PST | 17:00 CEST
⏱️ Duration: 30 minutes
As gene therapies continue to advance, ensuring robust adventitious agent testing is essential to maintaining product quality and patient safety. This presentation explores how Pacira BioSciences integrated Next-Generation Sequencing (NGS) into its quality control strategy for advanced gene therapy programs.
Discover why Pacira adopted NGS as a complementary method alongside traditional assays, the key steps taken to implement it within a risk-based quality control framework, and the practical lessons learned throughout the process.
Learn how Pacira collaborated with PathoQuest to implement NGS-based biosafety testing, strengthening product safety and enhancing viral risk mitigation for advanced therapies.
Key Takeaways:
- Why NGS was introduced as a complementary method for adventitious agent testing
- The key steps for implementing NGS within a risk-based quality control strategy
- Practical lessons learned from the Pacira–PathoQuest collaboration
🎤 Speaker
Po-Yi Ho
— Associate Director / Analytical Development / Cell & Gene Therapies at Pacira BioSciences Pacira
Po-Yi leads analytical strategy and assay development for gene therapies and advanced biologics, supporting product characterization, process development, and regulatory submissions across Pacira’s innovative therapeutic pipeline.
Don’t miss this opportunity to gain practical regulatory insights from industry experts.
